Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.

Clinical endocrinology - 1 Jan 2008

Mian Caterina, Barollo Susi, Pennelli Gianmaria, Pavan Nicodemo, Rugge Massimo, Pelizzo Maria Rosa, Mazzarotto Renzo, Casara Dario, Nacamulli Davide, Mantero Franco, Opocher Giuseppe, Busnardo Benedetto, Girelli Maria Elisa

Abstract excerpt

OBJECTIVE: Papillary thyroid cancers (PTCs) with no iodine uptake have an aggressive behaviour and a poor prognosis. The aim of our study was to characterize, at molecular level, a subset of PTC with no 131 iodine ((131)I) uptake. DESIGN AND METHODS: Forty-eight cancer tissues were divided into three groups: Group 1, 28 primary cancers; Group 2, 7 recurrences capable of trapping (131)I; and Group 3, 13...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary
Share to Glucose Transporter Type 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hexokinase

Share to Iodine Radioisotopes

Share to Sulfate Transporters

Share to Symporters

Share to Thyroglobulin

Share to Thyroid Cancer, Papillary

Source

Identifiers

PMID: 17854396
DOI: 10.1111/j.1365-2265.2007.03008.x

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.PMID 17854396Read ↗

Molecular and Proteomic Profiles of Radioiodine Refractory Papillary Thyroid CancerSemantic proximity Read ↗

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.Semantic proximity Read ↗

The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.Semantic proximity Read ↗

Expression of the Na+/I- Symporter Gene in Human Thyroid Tumors: A Comparison Study with Other Thyroid-Specific GenesSemantic proximity Read ↗

The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid CancerSemantic proximity Read ↗

BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine MetabolismSemantic proximity Read ↗

FDG PET/CT imaging in recurrent papillary thyroid cancer: does BRAF mutation status matter?Semantic proximity Read ↗

Do BRAFV600E mutation and sodium-iodide symporter expression affect the response to radioactive iodine therapy in patients with papillary thyroid carcinoma?Semantic proximity Read ↗

Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer.Semantic proximity Read ↗

Efficacy of Radioiodine in Non-Distant Metastatic Papillary Thyroid Cancer with TERT-p Mutation at Initial DiagnosisSemantic proximity Read ↗

The role of BRAF V600E mutation in post-surgical 131I therapy in papillary thyroid carcinoma: a study based on SPECT-CT uptake analysis.Semantic proximity Read ↗

Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.